arrogate H 2013 CONTENTS
BAP Officers and Council 4 General Information 5 Lifetime Achievement Award 7 2013 Prizes and Awards 8 Acknowledgements 9 Programme in Detail Sunday 28th July 10 Monday 29th July 12 Tuesday 30th July 24 Wednesday 31st July 36 BAP Membership 40
BAP OFFICE 36 Cambridge Place Hills Road Cambridge CB2 1NS
Tel: +44 (0)1223 358 395 Website: bap.org.uk
Executive Officer and Company Secretary Susan Chandler [email protected]
Assistant to the Executive Officer Lynne Harmer [email protected]
Education Co-ordinator and Digital Media Developer Sarah Channing-Wright [email protected]
The scientific material presented at this meeting reflects the opinions of the contributing authors and speakers. The British Association for Psychopharmacology accepts no responsibility for the contents of the verbal or any published proceedings of this meeting.
For reasons beyond our control we have the right to immediately alter or cancel the conference or any arrangements, timetable, plans or items relating directly or indirectly to the conference. The participants shall not be entitled to any compensation for damages that result from such alteration or cancellation. It is highly recommended that all participants carry the proper individual travel and health insurance.
The British Association for Psychopharmacology is registered in England as a Private Limited Company No 5866899. Registered Charity No 277825. Registered Office: 36 Cambridge Place, Hills Road, Cambridge CB2 1NS
1 1 BAP Summer Meeting 28-31 July 2013
Harrogate
2 2 arrogate H 2013 Hall H – Posters, Exhibition, Refreshments, Lunches
3 3 BAP Summer Meeting 28-31 July 2013
BAP OFFICERS AND COUNCIL MEMBERS
Until the 2013 Annual General Meeting (29 July, Hall D)
OFFICERS President: Barbara Sahakian (Cambridge) President-elect: Paul Harrison (Oxford) Past-President: Nicol Ferrier (Newcastle)) Honorary Treasurer: Catherine Harmer (Oxford) Honorary General Secretary: Peter Haddad (Manchester) Meetings Secretary: Jo Neill (Manchester) Secretary for Clinical External Affairs: Naomi Fineberg (Welwyn Garden City) Secretary for Non-Clinical External Affairs: Paula Moran (Nottingham)
COUNCIL Anne Jackson (Brighton) Val Curran (London) Steve Bazire (Norwich) Marcus Munafo (Bristol) Liz Tunbridge (Oxford) Mitul Mehta (London) Hugh Marston (Edinburgh) Peter Jones (Cambridge) Oliver Howes (London)
Co-opted Members: Jeffrey Nye (New Jersey) Mark Tricklebank (Windlesham)
Ex-Officio Council Members: BAP Editor: David Nutt (London) RCPsych Special Committee Chair: Allan Young (London) BAP Director of Education: Hamish McAllister-Williams (Newcastle)
BAP PAST PRESIDENTS Max Hamilton Malcolm Lader David Nutt Alec Coppen Brian Leonard Charles Marsden Philip Bradley Stuart Montgomery Guy Goodwin Merton Sandler Barry Everitt Clare Stanford Eugene Paykel Bill Deakin Thomas Barnes Susan Iversen Trevor Robbins Gavin Reynolds HONORARY MEMBERS Professor George Beaumont Dr Paul Leber Dr Alec Coppen Professor Brian Leonard Dr Timothy Corn Professor Eugene Paykel Professor Susan Iversen Professor Merton Sandler Professor Malcolm Lader Professor Hannah Steinberg GOVERNANCE PANEL Professor Charles Marsden (Chair) Dr Clare Stanford Professor Guy Goodwin
4 4 arrogate H 2013 GENERAL INFORMATION
All activities take place at Harrogate International Centre (HIC) unless stated otherwise
Abstract Supplement: The numbers next to the presentations and posters in this Programme are the abstract numbers as printed in the Supplement
BAP Annual General Meeting: Hall D on Monday at 17:00
Blogging: Suzi Gage, an active and well-known science blogger, will be in attendance at some of our sessions. Suzi is a PhD student in science and her blog posts appear on the Guardian website. Suzi has also been awarded one of the first BAP Public Communication Prizes, launched this year. The BAP blog posts will be hosted on the Guardian site and copied on the BAP website.
Certificates of Attendance: Will be emailed to attendees after the Conference, upon request
CPD: This meeting has been approved for Continuing Professional Development by the Faculty of Pharmaceutical Medicine and is eligible for 24 CPD points for full attendance.
Editorial Board Meeting (JoP): Meeting Room 1 on Tuesday at 12:45
Editorial Board Meeting (TA): Meeting Room 1 on Tuesday at 13:45
Exhibition: Hall H for the duration of the conference
Guest Lecture: Helen Mayberg, Hall D on Monday at 11:45
Internet Café: Foyer of Hall H
Luggage storage: A cloakroom will be available at Queen’s Suite for storing luggage on Wednesday morning
Lunch: Included in the registration fee in Hall H and outside Queen’s Suite on Monday and in Hall H on Tuesday
Mental Health Session: Approaches to novel drug development for treatment of psychiatric disorders – Hall D, Monday at 15:00
Name Badges: Must be worn at all times at HIC. If you lose your badge please collect another from the BAP desk. We recycle name badge holders – please leave yours at the BAP desk before departure
Photography and Recording: Prohibited during oral sessions except by the official BAP photographer. Please seek permission from the presenter if you wish to photograph any poster in Hall H
Post-doctoral Symposium: Translational autism research for drug discovery Queen’s Suite 1, Tuesday at 11:45
5 5 BAP Summer Meeting 28-31 July 2013
Posters: Session 1 13:00-15:00 on Monday - Affective Disorders 1 / Sleep and Circadian Rhythms / Learning and Cognition / Dementia / Anxiety / Educational Psychopharmacology / Brain Imaging Session 2 13:00-15:00 on Tuesday - Affective Disorders 2 / Neuropharmacology / Psychomotor Stimulants / Substances of Abuse / Schizophrenia
Posters may be mounted from 08:30 on Monday and, wherever possible, should remain in place until the end of the meeting on Wednesday. Poster presenters should stand by their poster for one hour during their designated session
Prize-giving: 2013 Prizes and Awards will be presented at the Conference Dinner on Tuesday
Psychopharmacology Award Oral presentations in Queen’s Suite 1 on Tuesday 16:00-17:00 Prize Winners:
Reception and The Royal Hall, Tuesday at 19:30 Conference Dinner: (for those who have purchased a ticket)
Refreshments: Included in the registration fee Available outside Queen’s Suite on Sunday 15:00-18:00 and in Hall H at designated breaks Monday onwards
Registration and Information: BAP desk outside the Queen’s Suite at the following times: Sunday 14:00-19:15 Monday 08:30-17:30 Tuesday 08:30-17:00 Wednesday 09:00-12:30
Satellite Symposia: Sunday – Sunovion, Queen’s Suite 2 at 17:15 Monday – Lundbeck, Queen’s Suite 1 at 13:00 Monday – Roche, Queen’s Suite 2 at 13:00 Monday – Janssen, Garden Room and Red Lounge at the Old Swan Hotel at 18:00
Short Oral Sessions: Tuesday 15:00-16:00 in Hall D and Queen’s Suite 1 & 2
Speaker Preview Room: Between Queen’s Suite and Hall D
Special Session: Supported by Servier, Queen’s Suite 1 on Sunday at 17:00
Symposia: 1, 4, 7 in Hall D; 2, 5, 8 in Queen’s Suite 1; 3, 6, 9 in Queen’s Suite 2
Welcome Reception and Buffet: Sunday 19:30 in the Wedgwood Restaurant and on the Front Lawn at the Old Swan Hotel
Wi-Fi cards: Available at the HIC information desk
Workshop: Sunday at 14:00-17:00 in King’s Suite Workshop on developing guiding principles on good practice with respect to animal behavioural studies
6 6 arrogate H 2013 2013 LIFETIME ACHIEVEMENT AWARD
The BAP Council is delighted to announce that the 2013 Lifetime Achievement Award will be presented to Professor Charles A Marsden
Charles was born in Cambridge in March 1943. He went to London University, obtaining his BSc Zoology in 1966. Although he acquired a place at Durham University to study ecology, he changed tack after reading an article describing the Falck- Hillarp formaldehyde fluorescence method to visualise monoamine containing pathways in the brain and went to Southampton University in 1967 to study for an MSc in Biochemical Pharmacology. Charles stayed on at Southampton to do a PhD on the cellular localisation of monoamines in invertebrate brain which he obtained in 1969.
He then became Assistant Lecturer at the University of Bergen, Norway (1969-1972) working with Hans Guldberg, after which he returned to the UK, becoming a Research Fellow (MRC) at the Institute of Neurology, London working with Gerald Curzon.
In 1977 Charles read an article by Ralph Adams in Nature on measuring 5-HT release by a new method, voltammetry, and received funding from the MRC to go on a sabbatical to Adams’ lab in Kansas and learn the technique. The result of this research visit was that Charles brought the electrochemical system for measuring monoamines back to the UK.
Charles was appointed as a Lecturer at The University of Nottingham on 1st January 1978. He was awarded a prestigious Wellcome Trust Senior Lectureship in August 1981 and became Reader in Neuropharmacology in 1983. He obtained his personal chair in Neuropharmacology in August 1986 and received a DSc from Southampton University in the same year. Charles became co-director of Institute of Neuroscience, with Peter Liddle in 2002 and together they set up an inclusive virtual research institute and established a newsletter to encourage research interaction, which has always been his style. Charles also helped a successful bid to establish the first small animal magnet at Nottingham. He has always had a proactive interest in training researchers and the interdisciplinary doctoral training scheme was another successful outcome of the Institute and reflects Charles’ ethos. In his time at Nottingham Charles supervised over 70 postgraduate students and over 30 post-doctoral research fellows worked with him. Many of these workers are now senior scientists in the UK and around the world.
The breadth of Charles’ scientific interests within psychopharmacology is impressive, as is his ability to move into new areas of research. He was among the first persons in the UK to undertake fluorescence histochemistry to map neuronal pathways in the brain. He can claim to be the first person in this country to have used in vivo voltammetry, helping others to set up this method. He was a pioneer in the use of high performance liquid chromatography coupled with electrochemical detection for the measurement of monoamines in the brain and he combined this technique with in vivo microdialysis to measure monoamine release in the conscious animal. He has also been much involved with work on brain neuropeptides and cannabinoids. Crucially, he is someone who has long recognised that studies on behaviour, particularly animal models of psychiatric disorders, should be linked with neurochemical studies, preferably in the same animal. Many of his over 300 published papers reflect this approach.
The commitment to psychopharmacology as a subject by Charles is demonstrated by the energy he has given to numerous societies. He has had a long-standing commitment to the British Association for Psychopharmacology (BAP), being on Council for 13 years (1991- 2004), Membership Secretary (1995-96), and has held virtually every other officer post including Programme Secretary (1996-1998), President Elect (1998-2000), President (2000-2002), Past President (2002–2004) and Chair of the Governance Panel (2010-2013). Charles has also made a major sustained contribution to the Serotonin Club as a committee member and in his role as Vice-President (1992–1994) and President (2002–2004). In 2012 he was made an honorary member of this scientific society, now renamed the International Serotonin Research Society. Both the Serotonin Club and the BAP flourished under his watchful eye for detail combined with an ability to engage all the membership.
Charles was on the editorial board of The British Journal of Pharmacology (1980-1987), a member of Committee of the British Pharmacological Society (1995-1999) and as BPS Representative on UKLSC (2001 - present). He was awarded JR Vane Medal by the British Pharmacological Society in 2002 for his outstanding contribution to neuropharmacology and a Fellowship of the British Pharmacological Society in 2006. Charles has also served on the editorial board of numerous other journals including Neuropharmacology, Psychopharmacology, Synapse and Neuroscience.
Charles Marsden has played a key role in the development and continuation of psychopharmacology in the UK for well over 40 years and has pioneered approaches to this science which many people now take for granted.
We are delighted that Charles will accept the 2013 Lifetime Achievement Award at the conference dinner on Tuesday 30 July.
7 7 BAP Summer Meeting 28-31 July 2013
2013 PRIZE WINNERS
BAP PSYCHOPHARMACOLOGY AWARDS To reward those working in non-clinical and clinical psychopharmacology Oral presentations will be on Tuesday 30 July at 16:00 in Queen’s Suite 1 The 2013 Psychopharmacology Award winners are: Angela Attwood (University of Bristol) Presentation title: D-cycloserine does not improve drug-related cue exposure: what can we learn from animal data? Jonathan Roiser (University College London) Presentation title: Individual differences in psychopharmacology: Where do they come from and why should we care? Kuan-Pin Su (China Medical University) Presentation title: Omega-3 fatty acids in depression: The biological, therapeutic and preventive implications
BAP/CAMBRIDGE COGNITION AWARD The BAP and Cambridge Cognition are strongly committed to promoting and encouraging research in the area of Psychopharmacology that could directly, and in the near term, translate to patient care. The BAP/Cambridge Cognition Award exists to support the development of novel assessments, treatments algorithms, interventions, or assistive technologies, and to particularly reward translational approaches in Psychopharmacology. The 2013 BAP/Cambridge Cognition Award recipient is Marcus Munafo, University of Bristol A poster describing his work, “Using prototypical faces in studies of emotion recognition“, will be displayed in Hall H
HANNAH STEINBERG BURSARY Thanks to the generosity of Professor Hannah Steinberg, a founding member of BAP, and the Wolfson Foundation, we are pleased to award a special bursary each year for attendance at the Summer Meeting. The recipient this year is Abigail Benn (Univ of Bristol). Abigail will present Poster MC19 on Monday and will present within the Short Oral Session ‘Windows on the Brain’ on Tuesday afternoon “Optogenetic stimulation of glutamatergic neurones in the rodent prefrontal cortex improves discrimination performance in an object recognition task”
**NEW** BAP PUBLIC COMMUNICATION PRIZES Launched this year, the BAP Public Communication Prizes will be awarded annually to reward excellence in both clinical and non-clinical science communication to the public in the area of psychopharmacology. There are two prizes: one for a Training Member and one for a Full Member. The awards will be presented at the Conference Dinner on Tuesday. The first winners are:
Suzi Gage (Training Member Prize) and Carmine Pariante (Full Member Prize)
Links to Suzi’s and Carmine’s public information articles are available at the BAP website.
POSTER PRIZES AND UNDERGRADUATE AWARDS Decisions will be made during the conference and winners announced at the Conference Dinner on Tuesday.
8 8 arrogate H 2013 BURSARIES The Council of BAP is committed to supporting young scientists with various initiatives. For the 2013 Summer Meeting we have awarded almost 60 bursaries to assist Training Members, Post-Docs and Undergraduates to attend the conference.
We are extremely grateful to the Gatsby Charitable Foundation for their generous contribution towards the 2013 bursary fund.
ACKNOWLEDGEMENTS
BAP acknowledges contributions from the following, who will take part in the 2013 summer meeting by supporting a Special Session, Satellites and exhibition stands
Janssen Campden Instruments Lundbeck Shire Roche Tracksys Servier Sunovion
POSTER PRESENTATIONS
l All posters must be exhibited in LANDSCAPE format.
l Posters may be mounted from 08:30 on MONDAY 29 JULY
l All posters must be mounted with the Velcro provided
l Conference staff will remove any poster carrying a different title to that which is on the accepted abstract
l Presenters should stand by their poster for one hour during their designated session
ORAL PRESENTATIONS
The time allocated to each oral presentation is to allow questions from, and discussion with, the audience. This interaction is an important component of BAP Summer Meetings, reflecting our philosophy of promoting discussion and debate. Keeping to time is particularly important as attendees often wish to hear talks in different sessions. Session chairs are asked to strictly enforce the time allocated to each presenter.
9 9 BAP Summer Meeting 28-31 July 2013
FULL PROGRAMME
PLEASE NOTE: All activities take place at Harrogate International Centre (HIC) unless stated otherwise
SUNDAY 28 JULY
14:00 Registration and Information desk opens outside Queen’s Suite
14:00-17:00 Workshop on developing guiding principles on good practice with respect to animal behavioural studies King’s Suite, HIC A joint initiative by the Laboratory Animals Association (LASA) the BAP, BNA and ESSWAP to develop guidance based on current expert opinion that offers advice on what researchers need to think about before embarking on animal behavioural studies
16:00 Tea and cakes outside Queen’s Suite for those attending the BAP Special Session or the Satellite Symposium at 17:00
17:00-19:00 BAP Special Session supported by Servier Queen’s Suite 1, HIC
Getting better at treating mood disorders: lessons from mechanistic and clinical studies Chaired by Oliver Howes (Inst of Psychiatry)
17:00 Welcome and Introduction Oliver Howes (Inst of Psychiatry)
17:10 What underlies antidepressant response and what this means for treatment Catherine Harmer (Univ of Oxford)
17:50 Getting them better and keeping them well Guy Goodwin (Univ of Oxford)
18:30 Discussion
19:00 End of session
10 10 Sunday arrogate H 2013
17:15-19:00 Satellite symposium hosted by Sunovion Queen’s Suite 2, HIC
Key challenges in antipsychotics’ tolerability Chaired by Thomas Barnes (Imperial College London)
17:20 Mechanisms of antipsychotic-induced metabolic side effects Gavin Reynolds (Sheffield Hallam Univ)
17: 4 5 Q & A
17:50 Monitoring the metabolic side effects of antipsychotics: a POMH-UK quality improvement programme Thomas Barnes (Imperial College London)
18 :15 Q & A
18:20 Antipsychotic induced hyperprolactinaemia: Problems and solutions Peter Haddad (Univ of Manchester)
18:45 Q&A and Closing Remarks
19:30 Welcome Reception at The Old Swan Hotel In the Wedgwood Restaurant and outside on the Front Lawn Delegates are invited to attend for drinks and a buffet meal Entertainment from the Chris White Jazz Trio and Stuart Fletcher Disco The BAP President, Barbara Sahakian, will give a short welcome address at 20:00
11 Sunday 11 BAP Summer Meeting 28-31 July 2013
MONDAY 29 JULY
08:30 BAP desk opens in the Foyer of the Queen’s Suite
09:00 Symposia 1, 2 and 3 in parallel Hall D, Queen’s Suite 1, Queen’s Suite 2
SYMPOSIUM 1 – Hall D The neurobiology of social behaviour: pharmacological manipulation and recent advances in therapy Chairs Jo Neill (Univ of Manchester) and Jørgen Scheel-Krüger (Aarhus Univ)
09:00 Antonia Hamilton (Univ of Nottingham) S01 Social behaviour and top-down control in autism
09:30 Jørgen Scheel-Krüger (Aarhus Univ) S02 Prenatal valproate as a rodent model for autism
10:00 Refreshments in Hall H
10:30 Louk Vanderschuren (Utrecht Univ) S03 The neurobiology of social play behavior in rats
11:00 Eric Prinssen (F.Hoffman-La Roche, Basel) S04 Discovering novel therapies for negative symptoms of schizophrenia by using rodent models of social withdrawal
SYMPOSIUM 2 – Queen’s Suite 1 Brain-derived neurotrophic factor (BDNF) and synaptic plasticity as a drug target for cognitive dysfunction in CNS disorders Chairs: Pradeep Nathan (Univ of Cambridge), Lilana Minichiello (Univ of Oxford)
09:00 Liliana Minichiello (Univ of Oxford) S05 BDNF-TrkB signaling in striatal enkephalinergic neurons controls inhibition of locomotor behaviour
09:30 Charlotte Oomen (Germany) S06 BDNF interacts with immature neurons in the hippocampus during memory and pattern separation
10:00 Refreshments in Hall H
10:30 Pradeep Nathan (Cambridge) S07 Effect of the BDNF Val66Met polymorphism on synaptic and cognitive function in healthy subjects
12 12 Monday arrogate H 2013
11:30 Paul Maruff (CogState Ltd, Melbourne) S08 Modulation of Aβ amyloid-related cognitive decline by brain-derived neurotrophic factor Val66Met polymorphism in preclinical Alzheimer’s disease
SYMPOSIUM 3 – Queen’s Suite 2 Experimental Medicine approaches in developing new treatments for anxiety disorders Chairs: David Baldwin (Univ of Southampton) and David Nutt (Imperial College, London)
09:00 Nic van der Wee (Leids Univ Medisch Centrum) S09 Where is the room for improvement in the drug treatment of anxiety disorders?
09:30 Gerry Dawson (P1vital Ltd, Oxford) S10 What has experimental medicine ever done for us?
10:00 Refreshments in Hall H
10:30 Sally Adams (Univ of Bristol) S11 What do studies of cognitive bias modification reveal?
11:00 Matt Garner (Univ of Southampton) S12 How good is the 7.5% CO2 inhalation model of Generalized Anxiety Disorder?
11:45 BAP ANNUAL GUEST LECTURE – Hall D Chaired by Barbara Sahakian
Rethinking Depression and its Treatment: Insights from Studies of Deep Brain Stimulation
Helen S Mayberg Professor of Psychiatry, Neurology and Radiology and the Dorothy Fuqua Chair in Psychiatric Imaging and Therapeutics at Emory University School of Medicine
Critical to the development of deep brain stimulation (DBS) as a novel therapy for patients with treatment resistant depression has been the characterization of brain systems mediating normal and abnormal mood states as well as those mediating successful and unsuccessful response to various antidepressant interventions using functional neuroimaging The theoretical and data-driven foundation for this new treatment strategy as well as results from ongoing experimental studies will be presented.
13 Monday 13 BAP Summer Meeting 28-31 July 2013
13:00-14:00 Satellite Symposium hosted by Lundbeck – Queen’s Suite 1
Opioid Modulators in Alcohol Dependence: Growing potential for treatment in a non-specialist setting Chaired by Anne Lingford-Hughes (Imperial College, London)
Opioid receptors and their and relevance to alcohol dependence David Nutt (Imperial College, London)
Emerging clinical data on new treatment modalities for alcohol dependence Jonathan Chick (Spire Hospital, Edinburgh)
13:00-14:00 Satellite Symposium hosted by Roche Products Ltd – Queen’s Suite 2
Shedding Light on Negative Symptoms of Schizophrenia Chaired by Bill Deakin (Univ of Manchester)
When the drugs don’t work: imaging data on the neurobiology of refractory symptoms in schizophrenia Oliver Howes (Inst of Psychiatry, London)
The trouble with negative symptoms David Taylor (Maudsley Hospital, London)
13:00-15:00 Poster Session 1 – Hall H
Affective Disorders 1 / Sleep and Circadian Rhythms / Learning and Cognition / Dementia / Anxiety / Educational Psychopharmacology / Brain Imaging
MONDAY GROUP A: AFFECTIVE DISORDERS 1
Antidepressants, polyunsaturated fatty acids and glucocorticoid pre-treatment modulate MA01 inflammatory responses in human hippocampal progenitor cells Horowitz MA, Anacker C, Wertz J, Pariante C, Zunszain P
Investigating the effect of pre-treatment sleep abnormalities on the emergence of MA02 interferon-α-induced depressive disorder in a cohort of HIV and hepatitis C virus coinfected patients Berry A, Fialho R, File A, Keller M, Tibble J, Haq I, Whale R
Depression and health-related quality of life in patients with hepatitis C undertaking MA03 interferon- alpha (IFN-A) treatment Borsini AB, Hepgul N, Mondelli V, Pariante CM
Interferon-alpha-induced depression: the involvement of the kynurenine and tryptophan pathway MA04 Hepgul N, Borsini A, Mondelli V, Hotopf M, Zunzsain P, Myint AM, Pariante CM
14 14 Monday arrogate H 2013
Omega-3 fatty acids in the prevention of interferon-alpha-induced depression MA05 Su KP Lai HC, Yang HT, Su WP, Peng CY, Chang JPC, Huang CL, Pariante CM
INFLAME-BEAT: Elevated inflammation and neurotoxic diversion in the kynurenine pathway of MA06 tryptophan metabolism in heart disease patients with depression Nikkheslat N, Zunszain PA, Barbosa IG, Parker JA, Tylee AT, Carvalho LA, Pariante CM
A systematic review of inflammatory biomarkers in relation to treatment-resistant affective MA07 disorder Strawbridge R, Cleare A, Papadopoulos A
Gene expression as predictors of antidepressant response using ROC Analysis in the GENDEP MA08 study Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunszain PA, McGuffin P, Pariante CM
Developing an animal model to study inflammation and stress in depression MA09 Musaelyan K, Zunszain PA, Meert TF, Pariante CM, Thuret S, Fernandes C
Exposure to antenatal depression, neonatal behavioural dysregulation and the MA10 hypothalamic-pituitary-adrenal (HPA) axis Previti G, Conroy S, Fantini E, Du Preez A, Osborne S, Zunszain P, Pawlby S, Aguglia E, Pariante C
The effect of chronic restraint stress on anxiety-related behaviour in the elevated plus maze in MA11 juvenile mice Sadler AM, Bailey SJ
Effects of intrauterine stress on adulthood age-related disease: a 25 year prospective investigation MA12 Plant DT, Pawlby S, Pariante CM
Hypothalamic-Pituitary-Adrenal (HPA) axis response to social stressors in depression, PTSD and MA13 psychosis Ciufolini S, Mondelli V, Kempton M, Pariante C, Dazzan P
Using growth mixture modelling to analyse diurnal cortisol data: a pilot study MA14 Wertz J, Nikkheslat N, Mondelli V, Conroy S, Osborne S, Vecchio C, Pauls A, Dazzan P, Pariante C, Zunszain P
Hair cortisol analysis in psychiatric illnesses - a review MA15 Herane A, Papadopoulos A, De Angel V, Risco L, Cleare A
The antiglucocorticoid augmentation of anti-depressants in depression (ADD) study: MA16 methods, recruitment and patient characteristics Ryles F, Landa S, McAllister-Williams RH, Watson S, Anderson IM, Apekey T, Barker S, Bulmer S, Farrow C, Finkelmeyer A, Gill N, Grunze HCR, Haddad PM, Hiley J, Hughes TA, Lloyd A, McColl EMM, Siddiqi N, Sinha B, Smith E, Steen N, Stevens L, Sturrock A, Symonds C, Yates S, Wainright J, Watkinson H, Williams K, Ferrier N
15 Monday 15 BAP Summer Meeting 28-31 July 2013
Aldosterone increases earlier than corticosterone in new animal models of depression: M A17 Is this an early marker for depression onset? Franklin M, Jezova D, Hlavacova N, Singewald N, Murck H
Aldosterone and blood pressure in young people at increased risk of depression MA18 Williams C, Mannie ZN, Diesch J, Franklin M, Leeson P, Cowen PJ
A novel animal model for autism MA19 Bertelsen F, Møller A, Landau AM, Scheel-Krüger J
Childhood trauma in bipolar disorder MA20 Dougall D, Watson S, Gallagher P, Porter RJ, Basu S, Palanichamy N, Moncrieff J, Ferrier IN, Young AH
Quetiapine’s effects on emotional processing and sleep oppose abnormalities seen in bipolar MA21 phenotype Rock PL, Harmer CJ, Foster R, Wulff K, Goodwin GM
A longitudinal examination of the effect of lithium maintenance therapy on glomerular function MA22 in patients with affective disorders: a population based cohort study (2000-2011) Clos S, Rauchhaus P, Severn A, Donnan P
Comparative analysis of treatments for the prevention of manic and depressive relapse in MA23 bipolar disorder Taylor MJ, Goodwin E
Melatonin In acute mania investigation (MIAMI-UK) - preliminary results from an RCT MA24 Economou A, Sharpley AL, Gibson J, Cordey J, deCrescenzo F, Lawson J, Voysey M, Rylands A, Al Taier H, Lennox A, Deb T, Loomes R, Kay R, Matthews N, Rendell J, Ahmad F, Geddes JR, Quested DJ
MONDAY GROUP B: SLEEP AND CIRCADIAN RHYTHMS
The effects of caffeine and glucose drinks on a simulated morning drive to work after restricted MB01 sleep Alford CA, Duggan B
Insomnia and risk taking MB02 Baker LD, Kenny L, Wingfield M, Lymn J, Wickens R, Savage J, Fairchild G, Baldwin DS, Garner M
Sleep disturbance and pain severity: The influence of affective and attentional state MB03 Harrison L, Wilson S, Munafo MR
Management of insomnia within general practice: a questionnaire and qualitative interview study MB04 Everitt H, Leydon G, Little P, Baldwin DS
16 16 Monday arrogate H 2013 MONDAY GROUP C: LEARNING AND COGNITION
Effects of levocetirizine (5 mg) and hydroxyzine (50 mg) on cognitive and psychomotor MC01 performance during simulated diving at 30 and 10 meters Kienhorst EAM, van Ooij PJAM, van Hulst RA, Verster JC
Profiling cognitive dysfunction across therapeutic areas using the Cambridge MC02 Neuropsychological Test Automated Battery (CANTAB) Hermans LF, Rock PL, Housden CR, Riedel W
D-cycloserine does not improve drug-related cue exposure: what can we learn from animal data? MC03 Attwood AS, Hogarth L, Adams S, Howell E, Munafo M Angela Attwood has won a 2013 BAP Psychopharmacology Award. She will present her work orally at 16:00 on Tuesday
Effects of reward expectancy on attentional bias for rewarding stimuli are outcome-specific MC04 Jedras P, Jones A, Field M This will also be presented orally at 15:30 on Tuesday
The effect of arousal on attentional bias to rewarding cues MC05 Jones A, Barrett-Pink C, Field M
Neurocognitive endophenotypes in adult Attention Deficit/Hyperactivity Disorder (ADHD) MC06 Pironti VA, Muller U, Lai MC, Suckling J, Bullmore E, Sahakian BJ
Recognition of Happiness and Sadness in Depressed Patients: A meta-analytic review MC07 Dalili MN, Penton-Voak IS, Munafo MR
Habenula responses during appetitive and aversive conditioning in Major Depressive Disorder MC08 Lawson RP, Nord CL, Seymour B, Dolan RJ, Dayan P, Weiskopf NW, Roiser JP
Face emotion recognition in depression: clarifying the role of childhood trauma MC09 Suzuki A, Poon L, Kumari V, Cleare A
Decision making and risk taking in young people at increased risk of depression MC10 Mannie Z, Williams C, Browning M, Cowen P
Evidence for specific task switching deficits in veganism MC11 Kehagia A
Methylphenidate modulates working memory networks and behavioural performance in TBI MC12 patients Manktelow AE, Menon DK, Sahakian BJ, Verma V, Stamatakis EA
The effect of Ketamine on functional connectivity and its modulation by Risperidone and MC13 Lamotrigine Joules R, Doyle OM, O’Daly O, De Simoni S, Mehta MA This will also be presented orally at 15:30 on Tuesday
17 Monday 17 BAP Summer Meeting 28-31 July 2013
The effect of MDMA administration on the pruning of decision trees MC14 Faulkner P, Huys Q, Curran HV, Nutt D, Carhart-Harris R, Erritzoe D, Dayan P, Roiser J This will also be presented orally at 15:45 on Tuesday
A proof-of-concept investigation of genotype-dependent noradrenergic effects on impulsivity MC15 Knight JA, Wade MA, Gibbs AA
Effects of BDNF and KIBRA single nucleotide polymorphisms on human memory related brain MC16 activation Schwab LC, Nathan PJ, Henson RN, Suckling J, Miskowiak KW, Ooi C, Tait R, Soltesz F, Lawrence P, Maltby K, Skeggs A, Miller SR, McHugh S, Guan X, Lu B, Bullmore E, Dodds CM
Cognitive profiles of selective 5-HT1A agonists in rodent models of sustained attention, MC17 impulsivity and working memory Fodder AF, Newman-Tancredi A, Varney M, Shoaib M
The behavioural response to the alpha2A adrenoceptor agonist, guanfacine, differs in MC18 neurokinin-1 receptor knockout (NK1R-/-) and wildtype mice Pillidge K, Grimmé AJ, Tsai YC, Heal DJ, Stanford SC
Optogenetic stimulation of glutamatergic neurones in the rodent prefrontal cortex improves MC19 discrimination performance in an object recognition task Benn A, Stuart SA, Barker GRI, Teschemacher A, Warburton EC, Robinson ESJ This will also be presented orally at 15:00 on Tuesday Abigail Benn has been awarded the 2013 Hannah Steinberg BAP Conference Bursary
The KIBRA polymorphism is associated with abnormal synaptic activity and behavioural MC20 performance during error processing Clarke CL, Nathan PJ, Lawrence P, Bentley G, Dodds C, Miller SR, Wille D, McHugh S, Byrne M, Belgrove M, Bullmore E, Soltesz F
The effect of BDNF val66met polymorphism “met load” on error processing MC21 Soltesz F, Lawrence P, Byrne M, Belgrove M, Croft R, Bentley G, Dodds C, Suckling J, Lu B, Bullmore E, Nathan P
MONDAY GROUP D: DEMENTIA
Behavioural and cognitive deficits in the hTau murine model of tauopathies MD01 Geiszler PC, Knapp S, Chambraud B, Baulieu EE, Pardon MC
Synaptic and cognitive deficits induced by intracerebroventricular injection of soluble amyloid-b MD02 oligomers in rats Harte MK, McLean S, Marsh S, Grayson B, Ficher N, Lefebvre T, Koziel V, Neill JC, Pillot T
Optimising [18F]-fallypride imaging for D2/3 receptor occupancy studies in Alzheimer’s Disease MD03 Clark-Papasavas C, Dunn JT, Greaves S, Mogg A, Brownings S, Nwosu B, Lui K, Marsden P, Joemon J, Cleij M, Kapur S, Kessler R, Howard R, Reeves SJ
18 18 Monday arrogate H 2013
Souvenaid®, a unique nutrient combination has been shown in clinical trials to improve memory MD04 in early Alzheimer’s Disease Smith N
Audit of anti-dementia drug prescribing in an inpatient setting MD05 Nazir E, Ilie L, Rees EFY
Prescribing of antipsychotics in patients with dementia in inpatient setting– is our practice MD06 mirroring the NICE Guidelines? Nazir E, Ilie L, Sammy M
Service evaluation: Impact of routine specialist assessments in an Elderly Mentally Infirm (EMI) MD07 nursing home Nazir E, Rees E, Davies J
MONDAY GROUP E: ANXIETY
Impact of remission of obsessive-compulsive disorder and syndrome on prognostication and ME01 treatment strategies Bergbaum CE, Fineberg NA, Hengartner MP, Gale T, Rössler W, Angst J
Developing a new schedule for assessing the onset of symptoms and latency to treatment in ME02 psychiatric disorders: an international comparison Palazzo MC, Dell’Osso B, Camuri G, Altamura AC, Baldwin DS
A dose of ruthlessness: interpersonal moral judgment is hardened by the anti-anxiety drug ME03 Lorazepam Perkins AM, Ettinger U, Leonard A, Krueger K, Dalton J, Mehta MA, Kumari V, Williams SCR
Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for ME04 psychotic depression in the STOP-PD study Davies SJC, Mulsant BH, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS
Effect of 7.5% CO2 inhalation on the human eye-blink startle response ME05 Pinkney VL, Wickens R, Miler J, Bamford S, Baldwin DS, Garner M
An investigation of neuroimmunological and cognitive factors in Generalised Anxiety Disorder ME06 - an association? Southgate BD, Tang Z, Rochester JJ, Browning T, Fairfield S, Loveless T, Ali B, Culliford D, Garner M, Baldwin D, Hou R
Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy ME07 volunteers Schmidt K, Cowen P, Harmer CJ, Tzortzis G, Burnet PWJ
19 Monday 19 BAP Summer Meeting 28-31 July 2013
The effect of prefrontal transcranial direct current stimulation on attention network function ME08 in healthy humans Miler JA, Meron D, Baldwin DS, Garner M This will also be presented orally at 15:45 on Tuesday
Comparable effects of 7.5% carbon dioxide inhalation and trait anxiety on attention control ME09 Garner M, Ainsworth B, Munafo MR, Baldwin DS
MONDAY GROUP F: EDUCATIONAL PSYCHOPHARMACOLOGY
Audit of Physical Health Monitoring in Old age Psychiatric inpatient unit Weller Wing Bedford MF01 Hospital Aftab A, Shah S, Haq R, Sule A
SSRI taking and emotional/clinical responding in Borderline Personality Disorder MF02 Zirk-Sadowski J, Singh R, Yathiraj K, Harwood S, Szalma B, Owens B, Colquhoun A, Denman C, Dudas R
Nature and prevalence of psychotropic drug prescribing for people with personality disorder MF03 Paton C, Bhatti SF, Crawford MJ, Barnes TRE
DARE To Make a Difference Project Evaluation (2011-2012) for Primary and Secondary Schools MF04 Nazir E
Translational Drug Discovery at the University of Sussex MF05 Atack J
MONDAY GROUP G: BRAIN IMAGING
Psychosis-like effects of ketamine - relationship to brain activity MG01 Stone J, Dietrich C, Reed L, De Simoni S, Mehta M, Krystal J, Barker GJ This will also be presented orally at 15:45 on Tuesday
The effect of MDMA on recollecting emotionally potent autobiographical memories: an fMRI MG02 study with implications for MDMA-assisted psychotherapy Carhart-Harris RL, Wall MB, Erritzoe D, Kaelen M, Ferguson B, De Meer I, Tanner M, Bloomfield M, Williams TM, Bolstridge M, Stewart L, Morgan C, Newbould RD, Feilding A, Curran HV, Nutt DJ
The anarchic brain: using dynamic causal modelling to assess the effect of psilocybin on effective MG03 connectivity within the default mode network Kaelen M, Kahan J, Moran J, Ham T, Wall M, Feilding A, Nutt D, Carhart-Harris RL
20 20 Monday arrogate H 2013
The effects of psilocybin and MDMA on hippocampal resting state functional connectivity MG04 Williams LTJ, Carhart-Harris RL, Erritzoe DE, Williams TM, Stone JM, Reed L, Tyacke RJ, Leech R, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ
Behavioural and neural responses to collective decision-making in humans MG05 Charpentier CJ, Moutsiana C, Garrett N, Sharot T
Effects of satiation on brain responses to rewarding and aversive stimuli MG06 Thomas JM, Higgs S, Dourish CT, Hansen P, Harmer CJ, McCabe C
Changes in synaptic GABA concentrations are not measurable using MR spectroscopy MG07 Myers JFM, Evans CJ, Kalk NJ, Edden RAE, Lingford-Hughes AR
Effect of naltrexone on neural reward and aversive processing; implications for compulsive MG08 disorders McCabe C, Murray E, Brouwer S, McCutcheon R, Harmer CJ, Cowen PJ
Investigation of TSPO status in the human brain in alcohol dependence: a [11C]PBR28 PET study MG09 Kalk NJ, Guo Q, Owen D, Waldman A, Dar K, Gunn RN, Nutt DJ, Rabiner EA, Lingford-Hughes AR
Imaging the imidazoline2 binding site with the novel PET ligand [11C]BU99008 in a higher MG10 species: Evaluation and characterisation Tyacke RJ, Parker CA, Nabulsi N, Holden D, Lin S-F, Labaree D, Kealey S, Gee AD, Husbands SM, Carson RE, Huang Y, Nutt DJ
Assessment of endogenous opioid peptide release with radioligand binding – In Vitro and Ex MG11 Vivo Studies with [3H]Diprenorphine and [11C]Carfentanil Quelch DR, Parker CA, Katsouri L, Lanzarone S, Nutt DJ, Tyacke RJ
Mapping stress responses using manganese-enhanced magnetic resonance imaging (MEMRI) MG12 Thakrar C
15:00 BAP Plenary Mental Health Session – Hall D Approaches to novel drug development for treatment of psychiatric disorders Chairs: Jeffrey S Nye (Janssen Pharmaceuticals) and Barbara J Sahakian (Univ of Cambridge)
15:00 Introduction Jeffrey Nye (Janssen Pharmaceuticals)
15:10 Development of rapidly acting antidepressant drugs Wayne Drevets (Laureate Inst for Brain Research)
15:30 Glutamatergic approaches for psychiatric disorders Joseph Wettstein (F. Hoffmann-La Roche Ltd)
21 Monday 21 BAP Summer Meeting 28-31 July 2013
15:50 Discussant Trevor Robbins (Univ of Cambridge)
16:10 Questions and Discussion with the audience Barbara Sahakian (Univ of Cambridge)
16:45 End of session
17:00 British Association for Psychopharmacology Annual General Meeting – Hall D BAP Members only Chaired by Professor Jo Neill, Meetings Secretary
1. Presidential Address
Professor Barbara Sahakian
2. Motions for approval:
2.1 That the Minutes of the 2012 Annual General Meeting be adopted as a correct record
Professor Barbara Sahakian
2.2 That the Editor’s Report be received
Professor David Nutt
2.3 That the Trustees/Directors Annual Report and audited accounts for the period 1 January to 31 December 2012 be received and adopted
Professor Catherine Harmer
2.3.a Proposal that the Full Membership subscription be increased to £100 from March 2014
Professor Catherine Harmer
2.4
22 22 Monday arrogate H 2013
That the Honorary General Secretary’s Report be received Dr Peter Haddad
2.5 That the Governance Panel’s Report be received
Professor Charles Marsden
3. Discussion
18:45-21:00 Satellite Symposium hosted by Janssen – Garden Room and Red Lounge, The Old Swan Hotel Drug development: Theory to practice Chaired by Peter Haddad (Univ of Manchester)
18.00-18.45 Arrival and buffet
18.45-19.00 Introduction & Welcome Peter Haddad (Univ of Manchester)
19.00 Can we improve nomenclature in psychopharmacology? David Nutt (Imperial College, London)
19:30 Drug development: Efficacy v Effectiveness Ludgar Hargartar (Janssen)
20.00 The place of observational studies in assessing the effectiveness of long acting injectable antipsychotics Peter Haddad (Univ of Manchester)
20.30 Q&A
23 Monday 23 BAP Summer Meeting 28-31 July 2013
TUESDAY 30 JULY
08:30 BAP desk opens in the Foyer of the Queen’s Suite
09:00 Symposia 4, 5 and 6 in parallel Hall D, Queen’s Suite 1, Queen’s Suite 2
SYMPOSIUM 4 – Hall D Imaging dopamine in the living brain Chairs: Elizabeth Tunbridge (Univ of Oxford) and Paul Harrison (Univ of Oxford)
09:00 Mark Ungless (Imperial College, London) S13 Listening to dopamine neurons using in vivo electrophysiology
09:30 Mark Walton (Univ of Oxford) S14 Using fast-scan cyclic voltammetry to visualise real-time dopamine release in
behaving animals
10:00 Refreshments in Hall H
10:30 Elizabeth Tunbridge (Univ of Oxford) S15 The impact of dopaminergic modulators on cognition
11:00 Philip McGuire (Inst of Psychiatry, London) S16 Neuroimaging of dopamine function in the human brain
SYMPOSIUM 5 – Queen’s Suite 1 Computational Psychopharmacology Chairs: Jonathan Roiser (University College London); Quentin Huys (Univ of Zürich)
09:00 Quentin Huys (Univ of Zürich) S17 An introduction to computational modelling for psychopharmacologists
09:30 Tiago Maia (Univ of Lisbon) S18 Catecholaminergic disturbances and attention-deficit/hyperactivity disorder
10:00 Refreshments in Hall H
10:30 Tim Behrens (Univ of Oxford) S19 Imaging competition mechanisms in living humans
11:00 Douglas Steele (Univ of Dundee) S20 Abnormal valuation in depression, schizophrenia and addiction
24 24 Tuesday arrogate H 2013 SYMPOSIUM 6 – Queen’s Suite 2 Alzheimer’s disease early detection and early effective treatment Chair: Barbara Sahakian (Univ of Cambridge)
09:00 John Hardy (University College London) S21 Genetic analysis points to microglial activation as a key event in the pathogenesis of Alzheimer’s disease
09:30 Wim Riedel (Cambridge Cognition) S22 Enabling early detection and intervention in dementia
10:00 Refreshments in Hall H
10:30 John O’Brien (Univ of Cambridge) S23 Neuroimaging as a biomarker for different forms of dementia
11:00 Jeffrey Nye (Janssen Pharmaceuticals) S24 Disease modifying drugs for Alzheimer’s disease: perspectives from a drug developer’s point of view
11:45-12:45 BAP Post-doc Symposium – Queen’s Suite 1 Translational autism research for drug discovery Chair: Stephanie McTighe (Pfizer, Massachusetts)
11:45 Stephanie McTighe (Massachusetts) PD1 Impaired learning and attention in the BTBR mouse model of autism
12:00 Michael Schmeisser (Ulm Univ) PD2 Translational aspects in Shank mutant mice
12:15 Jamie Horder (Inst of Psychiatry, London) PD3 Multimodal neuroimaging in the search for autism treatment targets
12:30 Hilgo Bruining (Rudolf Magnus Inst, Utrecht) PD4 Disruption of a protocadherin gene identified by QTL mapping of social memory in mice, offers a model to study pervasive defects in behavior and cortical development
12:45 Editorial Board Meetings – Meeting Room 1 For Journal of Psychopharmacology and Therapeutic Advances in Psychopharmacology
13:00-15:00 Poster Session 2 in Hall H
Affective Disorders 2 / Neuropharmacology / Psychomotor Stimulants / Substances of Abuse / Schizophrenia
25 Tuesday 25 BAP Summer Meeting 28-31 July 2013
TUESDAY GROUP A: AFFECTIVE DISORDERS 2
Acute treatment with 13-Cis-retinoic acid induces a dose-dependent negative cognitive affective TA01 bias in rats Clarke B, Stuart SA, Robinson ESJ
Central amygdala lesions block antidepressant-induced positive affective bias in rats TA02 Stuart SA, Butler P, Nutt DJ, Robinson ESJ
Elevated VMAT1 expression associated with transient post-natal fluoxetine exposure in Wistar TA03 rats correlates with behavioural despair Regan CM, Hedigan K, Murphy KJ
Effects of Reboxetine on emotional processing in healthy volunteers may be determined by TA04 COMT val158met genotype Mowlem FD, Bautista CE, Gibbs AA
Adverse effects from antidepressant treatment: Findings from the GENPOD study TA05 Crawford A, Lewis S, Nutt D, Peters TJ, Cowen P, O’Donovan MC, Wiles N, Lewis G
Next generation sequencing: Beyond genetic association TA06 Fox JC, Carr TH, Keeler S, McLoughlin MJ, McCarthy DJ, Ng M, Runswick S
Anti-anhedonic effects of ketamine and its neural correlates in depression TA07 Lally N, Nugent AC, Luckenbaugh DA, Roiser JP, Zarate CA Jr This will also be presented orally at 15:15 on Tuesday
Efficacy and tolerability of transcranial direct current stimulation in major depression: TA08 a systematic review Meron D, Garner MJ, Baldwin DS
Diagnostic Status predictions using structural and functional MRI in major depression TA09 Johnston BA, Gradin VB, Mwangi B, Stirling M, Walker K, MacFarlane J, Matthews K, Steele D
Investigating dimensions of reward as trait markers for depression TA10 McCabe C
Aberrant reward learning in patients with functional movement disorders and unmedicated TA11 major depression Nord CL, Winston JS, Parees I, Huys QJM, Roiser JP, Edwards MJ, Dolan RJ
Electrophysiological correlates of self-blaming bias in remitted major depressive disorder TA12 Gethin JA, El-Deredy W, Lythe K, Zahn R
Screening for physical health problems in mood disorder service outpatients TA13 Lack DA, Holt RIG, Baldwin DS
26 26 Tuesday arrogate H 2013
Subjective symptom severity and long-term outcome of treatment-resistant depression TA14 Schoeler T, Rane LJ, Fekadu A, Wooderson S, Poon L, Markopoulou K, Strawbridge B, Cleare AJ
Long term outcome in patients treated in a specialist inpatient unit for treatment resistant TA15 depression Wooderson SC, Fekadu A, Markopoulou K, Rane LJ, Poon L, Juruena MF, Cleare AJ
Depression in pregnancy: adverse obstetric and foetal outcomes TA16 Sundaresh S, Conroy S, Osborne S, Pawlby S, Marsh MS, Pariante CM
Do your neighbours matter? Ethnic density in women with postnatal depression and with TA17 personality disorder in London, UK Du Preez A, Conroy S, Pariante CM
Real-time fMRI neurofeedback can improve amygdala regulation during emotional stimulation TA18 Brühl AB, Scherpiet S, Sulzer J, Stampfli P, Seifritz E, Herwig U
TUESDAY GROUP B: NEUROPHARMACOLOGY
Evidence for lithium-like effects of ebselen on 5-HT2A receptor function mediated via TB01 IMPase inhibition Antoniadou I, Arsiwala T, Buchmueller D, Kouskou M, Singh N, Vasudevan S, Churchill G, Sharp T
THC elicits very high-frequency gamma oscillations TB02 Morrison PD, Nottage J, Englund A, ffytche D
Dopamine D3 receptor blockade via genetic deletion or the novel atypical antipsychotic TB03 S33138 increases adult neurogenesis Egeland MT, Svenningsson P, Millan MJ
Neurotoxin-induced loss of cholinergic function in the dorsal striatum of wildtype mice TB04 causes locomotor hyperactivity in the light/dark exploration box Grimmé AJ, Nutter K, Hunt SP, Stanford SC
P-glycoprotein and CNS antihistamine effects in healthy volunteers TB05 Conen S, Theunissen EL, Vermeeren A, Mehta M, Ramaekers JG
Buprenorphine augmentation in the treatment of refractory OCD TB06 Aziz VM, Liddell MB, Briggs P, Kanakkehewa N, Rawi O, Roberts E
Effect of lisdexamfetamine in a rat model of binge-eating disorder TB07 Heal DJ, Vickers SP, Hackett D, Hutson PH
27 Tuesday 27 BAP Summer Meeting 28-31 July 2013
Pharmacokinetic and pharmacodynamic profiles of the prodrug stimulant lisdexamfetamine TB08 dimesylate in children and adolescents with ADHD Coghill D, Sorooshian S, Ermer J, Adeyi B, Squires L, Civil R
Post hoc responder analyses comparing the efficacy of lisdexamfetamine dimesylate and TB09 osmotic-release oral system methylphenidate in children and adolescents with attention-deficit/ hyperactivity disorder Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Adeyi B, Anderson C, Higgins N, Squires L, Civil R
TUESDAY GROUP C: PSYCHOMOTOR STIMULANTS
The neurodevelopmental and behavioural effects of methamphetamine exposure during TC01 pregnancy in rats McDonnell Dowling K, MacEoin V, Walsh S, O’Brien S, Kelly JP
The effects of different routes of administration of methylphenidate on attention and TC02 impulse control in a novel 5CSRTT Wood CM, Abdelkadar S, Palmer Z, Robinson ESJ
Low performing rats model the inattentive subtype of adult ADHD in the 5-choice TC03 continuous performance task (5C-CPT) Tomlinson A, Neill JC, Marshall KM
Reactivation of Mecp2 reverses behavioural abnormalities in a female mouse model of TC04 Rett Syndrome Riedel G, Robinson L
Genotype-dependent noradrenergic effects on memory: a proof-of-concept study TC05 Wade M, Knight J, Gibbs A
Methylphenidate induced psychosis: A systematic review of current literature TC06 Chikodzore MLD, Brink L
TUESDAY GROUP D: SUBSTANCES OF ABUSE
Avoidance of health warning information among cigarette smokers TD01 Maynard OM, Attwood A , O’Brien L, Brooks S, Hedge C, Leonards U, Munafo MR
A behavioural measure of sensation-seeking in humans TD02 Norbury A, Kurth-Nelson Z, Dayan P, Roiser JP, Husain M
28 28 Tuesday arrogate H 2013
Pramipexole decreases urges to smoke and redresses an imbalance between drug and TD03 non-drug reward Freeman TP, Das RK, Kamboj SK, Curran HV This will also be presented orally at 15:00 on Tuesday
Effects of acute anxiogenuc challenge on goal-directed control of human drug seeking behaviour TD04 Davidson AH
Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary evidence TD05 Das RK, Morgan CJA, Joye A, Curran HV, Kamboj, SK
The acute and chronic effects of cannabinoids on emotional processing TD06 Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Wollenberg O, Carter V, Morgan CJA, Curran, HV
Recreational drugs and sexual experiences: a cross-sectional internet survey TD07 Lawn WM, Winstock AR
Distinguishing trustworthy and untrustworthy faces in methadone/buprenorphine maintained TD08 opiate users Mokrysz CA, Wellington C, Charles M, O’Ryan D, Curran HV
Internal and Test-Retest Reliability of the Modified Stroop and the Disengagement Task TD09 Ataya A, Adams S, Attwood AS, Munafo M
Resting state synchrony in anxiety-related circuits of abstinent alcohol dependent patients TD10 Orban C, McGonigle J, Erritzoe D, Kalk NJ, Rabiner EA, Nutt DJ, Lingford-Hughes AR
Lapses of attention during driving in the alcohol hangover state TD11 Bervoets AC, de Klerk S, Vreman RA, Olivier B, Brookhuis KA, Roth T, Verster JC
Severity of Alcohol dependence and Craving: Components of the Desire for Alcohol TD12 Questionnaire Sinclair JMA, Pasche SC, Garner MJ, Baldwin DS
Computer assisted self-infusion of ethanol (CASE): A prediction of the future risk for addiction? TD13 Mick I, O’Connor S, Vitvitskiy V, Winiecki P, Mann KF, Zimmerman US
I bibi ergo sum (I have drunk therefore I am) TD14 Christiansen P, Jones A, Rigby P, Field M
Caffeine alters the behavioural and thermoregulatory responses to mephedrone without TD15 causing long-term neurotoxicity Shortall SE, Byatt S, Kaufman N, Lipman H, Smith G, Green AR, Fone KCF, King MV
Mephedrone, Cannabis and Alcohol: The new risks to mental health TD16 Cullen AB, Parrott A
29 Tuesday 29 BAP Summer Meeting 28-31 July 2013
Structural differences in the brain associated with heavy Ketamine use TD17 Cole AJ, Stone JM, Pepper FS, Furby H, Howes O, Morgan CJA
Establishing Pavlovian to instrumental transfer with orally delivered nicotine and fentanyl TD18 in rats: route to developing more effective drug cessation medications Fisher BF
Profiles of lisdexamfetamine, methylphenidate and modafinil as positive reinforcers in rats TD19 trained to self administer cocaine Heal DJ, Buckley NW, France CP, Hackett D
TUESDAY GROUP E: SCHIZOPHRENIA
An audit of antipsychotic prescription practice in a psychiatric service TE01 Achor M
Prevalence of high-dose and combined antipsychotic prescribing in mental health services TE02 across time and clinical settings Barnes TRE, Adroer R, Paton C
Evaluating the use of intramuscular clonazepam in rapid tranquilisation TE03 Bleakley S, Ekelund A, Henry R
Antipsychotics prescribing trends and patterns among children and adolescents with severe TE04 mental illness in Taiwan - a longitudinal population-based study Chang HC, McCrone P, Su KP
Clozapine augmentation in a low secure forensic service TE05 Deslandes PN, Sewell RDE
Practitioner attitudes to Clozapine initiation TE06 Gee SH, Taylor DM
Effects of antipsychotics on bone mineral density and prolactin levels in patients with TE07 schizophrenia: a 12 months prospective study in China Hou R, Wang M, Jian J, Mi G, Qiu H, Cao B, Tang M
Is the quality of reporting for antipsychotic Phase II/ III trials good enough? TE08 Patel MX, Collins S, Hellier J, Bhatia G
Paliperidone Palmitate for recurrent oculogyric crisis in a patient with schizophrenia TE09 Ramasamy K, Bhandari N
MTHFR 677C/T genotype is associated with antipsychotic drug-induced weight gain in TE10 patients with schizophrenia Srisawat U, Dalton CF, Reynolds GP
30 30 Tuesday arrogate H 2013
DNA methylation of the 5-HT1A receptor gene promoter is associated with negative TE11 syndrome response to antipsychotic drug treatment Tang H, Srisawat U, Dalton CF, Zhang ZJ, Reynolds GP
Cohort study of paliperidone palmitate long acting injection treatment in Sussex TE12 Whale R, Fialho R
Severe cognitive impairment within a multiply affected South Asian family with a high risk TE13 of schizophrenia Beetschen ER, Tomlinson A, Harte M, Mahmood T, Neill JC
Altered hippocampal and striatal function during salience processing in people at ultra TE14 high risk for psychosis Bossong MG, Allen P, Howes OD, Samson C, Quinn B, Bonoldi I, McGuire P
Compromised myelin integrity and peripheral inflammatory markers in first episode psychosis TE15 Giordano A, Deoni S, McMullen, Farid A, Simmons A, Morgan C, Reis Marques T, Mondelli V, Pariante C, Turkheimer F, Williams S, Dazzan P
Effect of inflammation on mental and physical clinical outcomes in first episode-psychosis TE16 Russell AE, Ciufolini S, Di Forti M, Giordano A, Marques TR, Taylor H, Morgan C, Murray RM, Dazzan P, Pariante CM, Mondelli V
Relationship between thalamic glutamate levels and clinical outcome in individuals at ultra TE17 high risk for psychosis Egerton A, Stone J, Chaddock C, McGuire P
Can we use cortisol levels to predict clinical outcome in patients with first-episode psychosis? TE18 Mondelli V, Ciufolini S, Handley R, Marques TR, Taylor H, Zunszain P, Di Forti M, Murray RM, Dazzan P, Pariante CM
Altered neurochemical profile in the rat prefrontal cortex following maternal immune activation: TE19 a longitudinal in vivo 1H magnetic resonance spectroscopy study Vernon AC, Lythgoe DJ, Williams SCR, So PW, Kapur S This will also be presented orally at 15:15 on Tuesday
Assessment of working memory and social behaviours in mice with genetic modification of the TE20 schizophrenia-risk gene MAP2K7 Wilson C, Thomson DM, Morris B, Pratt JA
Rats reared in isolation from weaning show increased expression of glutamate transporters and TE21 glutamate uptake in the prefrontal cortex and hippocampus Fachim HA, Bosaipo NB, Moriyama KK, Santos MR, Iyomasa MM, Beleboni RO, Rosa MLNM
Disc1 mutation induced alterations in cerebral metabolism and in the response to acute TE22 ketamine treatment: a comparison of three different Disc1 mutations Dawson N, Winchester CL, McVie A, Thomson DM, Dunlop J, Brandon NJ, Morris BJ, Pratt JA This will also be presented orally at 15:00 on Tuesday
31 Tuesday 31 BAP Summer Meeting 28-31 July 2013
Evaluation of sub-chronic ketamine treatment in a rodent model of the Iowa Gambling Task TE23 Jermy B, Rix R, Shoaib M
Chronic administration of haloperidol in naive rats; consequences for cerebral morphology TE24 and inflammation Bloomfield PS, Howes OD, de Paola V
Preliminary findings of a novel electrophysiological assay for NMDA receptor autoantibodies TE25 in psychosis Adams T, Watson S, Wilson S, Carroll B, Melody J, Garg H, MacMillan I, Brydon T, Hall S, Cunningham M This will also be presented orally at 15:30 on Tuesday
15:00-16:00 SHORT ORAL PRESENTATIONS – Hall D, Queen’s Suite 1 and Queen’s Suite 2
SHORT ORALS 1 – Hall D Special K: New Horizons Chair: David Nutt
15:00 DISC1 mutation induced alternations in cerebral metabolism and in the TE22 response to acute ketamine treatment: A comparison of three different DISC1 mutations Neil Dawson (Winchester CL, McVie A, Thomson DM, Dunlop J, Brandon NJ, Morris BJ, Pratt JA)
15:15 Anti-anhedonic effects of ketamine and its neural correlates in depression TA07 Niall Lally (Nugent AC, Luckenbaugh DA, Roiser JP, Zarate CA Jr)
15:30 The effect of ketamine on functional connectivity and its modulation by MC13 risperidone and lamotrigine Richard Joules (Doyle OM, O’Daly O, De Simoni S, Mehta MA)
15:45 Psychosis-like effects of ketamine – relationship to brain activity ME01 Mitul Mehta (Stone J, Dietrich C, Reed L, De Simoni S, Krystal J, Barker GJ)
32 32 Tuesday arrogate H 2013
SHORT ORALS 2 – Queen’s Suite 1 Windows on the Brain Chair: Kevin Fone
15:00 Optogenetic stimulation of glutamatergic neurones in the rodent prefrontal MC19 cortex improves discrimination performance in an object recognition task Abigail Benn (Stuart SA, Barker GRI, Teschemacher A, Warburton EC, Robinson ESJ)
15:15 Altered neurochemical profile in the prefrontal cortex following maternal TE19 immune activation: A longitudinal in vivo 1H magnetic resonance spectroscopy study Anthony Vernon (Lythgoe DJ, Williams SCR, So PW, Kapur S)
15:30 Preliminary findings of a novel electrophysiological assay for NMDA TE25 receptor autoantibodies in psychosis Tom Adams (Watson S, Wilson S, Carroll B, Melody J, Garg H, MacMillan I, Brydon T, Hall S, Cunningham M)
15:45 The effect of prefrontal transcranial direct current stimulation on attention ME08 network function in healthy humans Joanna Miler (Meron D, Baldwin DS, Garner M)
SHORT ORALS 3 – Queen’s Suite 2 Reward and Choice Chair: Val Curran
15:00 Pramipexole decreases urges to smoke and redresses an imbalance TD03 between drug and non-drug reward Tom Freeman (Das RK, Kamboj SK, Curran HV)
15:15 Investigating reward function as a biomarker and target for MG08 pharmacological treatments TA10 Ciara McCabe
15:30 Effects of reward expectancy on attentional bias for rewarding stimuli MC04 are outcome-specific Pawel Jedras (Jones A, Field M)
15:45 The effect of MDMA administration on the pruning of decision trees MC14 Paul Faulkner (Huys Q, Curran HV, Nutt D, Carhard-Harris R, Erritzoe D, Dayan P, Roiser J)
33 Tuesday 33 BAP Summer Meeting 28-31 July 2013
16:00 BAP Psychopharmacology Award Winners – oral presentations – Queen’s Suite 1 Chaired by Paul Harrison
16:00 Angela Attwood (University of Bristol) PW2 D-cycloserine does not improve drug-related cue exposure: what can we learn from animal data?
16:20 Jonathan Roiser (University College London) PW3 Individual differences in psychopharmacology: Where do they come from and why should we care?
16:40 Kuan-Pin Su (China Medical University) PW4 Omega-3 fatty acids in depression: The biological, therapeutic and preventive implications
19:30 Reception and Conference Dinner at The Royal Hall, Harrogate
34 34 Tuesday arrogate H 2013
Conference Dinner
Smoked Salmon and Asparagus Tartlet with Chicory Leaves and Wharfe Valley Lemon Oil
Vine Tomato, Buffalo Mozzarella and Sun Blush Tomato Stack with Pesto Dressing, Aged Balsamic and Olive Oil (For those who have ordered a vegetarian meal)
-o0o-
Rack of Lamb with a Redcurrant and Rosemary Jus
Roasted Pumpkin and Vegetable Brochette, Chargrilled Spears of Asparagus, Wild Rice and Spiced Tomato Dressing (For those who have ordered a vegetarian meal)
-o0o-
Yorkshire Clotted Cream with Strawberry Millefeuille and Strawberry Coulis
Dinner will be followed by the presentation of the 2013 BAP Awards
35 Tuesday 35 BAP Summer Meeting 28-31 July 2013
WEDNESDAY 31 JULY
09:00 BAP Desk opens in the Foyer of the Queen’s Suite
09:30 Symposia 7, 8 and 9 in Hall D, Queen’s Suite 1 and Queen’s Suite 2
SYMPOSIUM 7 – Hall D Can psychological constructs make good drug targets? The example of salience dysregulation in schizophrenia Chairs: Paula Moran (Univ of Nottingham), Colm O’Tuathaigh (University College Cork)
09:30 Paula Moran (Univ of Nottingham) S25 Assessing antipsychotic drug effects on salience in animal models
10:00 Colm O’Tuathaigh (University College Cork) S26 Salience as a behavioural phenotype in genetic and pharmacological animal models of schizophrenia
10:30 Refreshments in Hall H
11:00 Anton Loonen (Univ of Groningen) S27 Clinical studies of salience dysregulation and implications for nosology of schizophrenia
11:30 Peter Liddle (Univ of Nottingham) S28 The salience network in schizophrenia and its potential as a new treatment target for schizophrenia
SYMPOSIUM 8 – Queen’s Suite 1 Novel innovation in monitoring symptoms and treatments for schizophrenia and bipolar disorder Chair: Barbara Sahakian (Univ of Cambridge)
09:30 Torgny Svensson (Karolinska Inst) S29 Novel and improved pharmacological treatment in schizophrenia
10:00 Gary Gilmour (Lilly, Windlesham) S30 Novel mGlu5 positive allosteric modulator
10:30 Refreshments in Hall H
11:00 Clare Killikelly (Univ of Cambridge) S31 Cognitive training in schizophrenia
36 36 Wednesday arrogate H 2013
11:30 Guy Goodwin (Univ of Oxford) S32 Monitoring symptoms in bipolar patients: TrueColours
SYMPOSIUM 9 – Queen’s Suite 2 The impact of inflammatory challenges on mental function Chairs: Carmine Pariante (Inst of Psychiatry, London), Brian Leonard (National Univ of Ireland, Galway)
09:30 Matthew Taylor (Inst of Psychiatry, London) S33 Effect of interferon-alpha treatment on cortical glutamatergic function
10:00 Aye Mu Myint (Ludwig Maximilian Univ, Munich) S34 Inflammation and the generation of neurotoxins: can the activation of the tryptophan-kynurenine pathway in depression and schizophrenia suggest novel targets for psychotropic drug development?
10:30 Refreshments in Hall H
11:00 Neil Harrison (Univ of Sussex) S35 Inflammatory effects on medial temporal lobe metabolism impair human spatial memory
11:30 John Cryan (University College Cork) S36 The gut-brain axis and inflammation in major psychiatric disorders: Could this be a new approach to modulating abnormal brain function?
12:00 End of the 2013 Summer Meeting
37 Wednesday 37 BAP Summer Meeting 28-31 July 2013
Come and join the celebrations for the 40th anniversary of the BAP
Sunday 20 – Wednesday 23 July
Robinson College and West Road Concert Hall, Cambridge Social occasions at The Fitzwilliam Museum and Girton College
Confirmed Symposia:
Monday 21 July 1. Predictors of clinical response in depression 2. Tobacco addiction in schizophrenia: a translational investigation 3. ADHD and obesity: Overlapping neurobiology and development of pharmacological treatments
Tuesday 22 July 4. The adolescent brain – A key stage in the development of psychiatric disorders? 5. Chickens and Eggs: Separating Cause and Effect in Drug Addiction 6. Genetic pathways in Psychosis: the road to new treatments?
Wednesday 23 July 7. Endocannabinoids in psychiatry: current understanding and future treatments 8. The Electronic Cigarette: from Basic Pharmacology to Smoking Harm Reduction and Cessation 9. Dopamine, impulse control disorders and Parkinson’s disease
David Nutt will present the 2014 Guest Lecture
Plenary Mental Health Session: Is psychiatric diagnosis relevant to psychopharmacological treatment?
38 38 arrogate H 2013 THE BRITISH ASSOCIATION FOR PSYCHOPHARMACOLOGY
The BAP was founded in 1974, with the general intention of bringing together those from clinical and experimental disciplines as well as members of the pharmaceutical industry involved in the study of psychopharmacology. To this end the Association arranges scientific meetings, fosters research and teaching, encourages publication of results of research and provides guidance and information to the public on matters relevant to psychopharmacology, where appropriate.
The BAP has an extensive educational portfolio. The Certificate in Clinical Psychopharmacology provides up-to-date CPD and consists of six modules held each year – Anxiety Disorders, Schizophrenia, Affective Disorders, Substance Misuse, Old Age Psychiatry, Child and Adolescent Psychopharmacology.
Twice yearly the BAP holds three-day Masterclasses in central London. These immensely popular courses update practicing healthcare professionals on current issues in psychopharmacology and are taught by leading UK psychopharmacologists.
Since 2011 the BAP has offered an Online CPD Resource, a regularly-updated resource presented by acknowledged experts and opinion leaders in their respective fields.
The BAP launched the Pre-clinical Certificate in Psychopharmacology in July 2001, to increase awareness of, and expertise in, pre-clinical psychopharmacology through the provision of a series of training modules that covered key aspects of research on animals and humans as well as career development. The modular course has evolved over the years and will be re-launched in February 2014 as a 4-day residential course in Cambridge.
Membership of BAP is open to any qualified worker in a discipline relevant to psychopharmacology. Existing members include pharmacologists, psychiatrists, psychologists, neurobiologists and pharmacists.
Full Membership: Applicants are eligible for Full Membership if they can demonstrate involvement in areas relevant to psychopharmacology by, for example, qualifications, publications or research activity.
Training Membership: This category is designed to support scientists early in their career who have a limited income such as a research studentship. For this reason training membership is not available to medical applicants (i.e. doctors) other than in exceptional cases when it may be awarded at the discretion of the Honorary General Secretary. In addition training membership will only be awarded to those registered for a University research degree e.g. MSc, PhD. BAP supports training members attending the summer meetings by offering a reduced registration rate and the option to apply for a bursary if presenting data (see more detailed criteria on website). Training membership is limited to a 5-year maximum period (from the point of registration as a trainee member) or until the trainee attains a permanent position (e.g. in academia or a company).
Benefits of BAP membership include: • FREE subscription and online access to the Journal of Psychopharmacology* • Reduced registration fees for the annual Summer Meeting • Half price subscription to the Online CPD Resource • Eligibility for prizes and awards • Student bursaries for the BAP Summer Meeting • Reduced registration fees for selected partner association events • BAP Newsletter • Voting for BAP Officers and Council* • Being part of one of the largest national psychopharmacology associations in the world
*Full members only
Apply for membership now at the website http://bap.org.uk/membership
39 39 BAP Summer Meeting 28-31 July 2013
APPLICATIONAPPLICATION FOR FOR MEMBERSHIPMEMBERSHIP OF THETHE BAP BAP
ThisThis application application must must include include either the either name of th a Fulle name Member of of a BAP Full willing Member to support of the BAP applicant, willing to support the applicant,or a copy or of thea copy applicant’s of the curriculum applicant’s vitae curriculum vitae
TITLE ...... FIRST NAME ...... LAST NAME......
DATE OF BIRTH ......
APPLYING FOR: FULL MEMBERSHIP @ £80 p.a.
TRAINING MEMBERSHIP* @ £20 p.a. *This requires a supporting statement from your BAP sponsor
CURRENT WORK ADDRESS: ......
......
TEL: ...... FAX:......
EMAIL: ......
Year of PhD award (if applicable) ......
DEGREES (including dates and awarding body)
......
PRESENT POST: ......
PLEASE TICK THAT WHICH BEST DESCRIBES YOUR STATUS/INTEREST:
Clinical Pre-clinical Industrial Other
ARE YOU RESEARCH ACTIVE? Yes No
SPECIFIC INTEREST IN PSYCHOPHARMACOLOGY (i.e. psychiatric, psychological, experimental, pharmaceutical)
......
NAME OF BAP FULL MEMBER WILLING TO SPONSOR THIS APPLICATION:
......
SIGNATURE OF APPLICANT: ...... DATE: ......
*SUPPORTING STATEMENT FOR SPONSORS OF TRAINING MEMBERSHIP APPLICANTS I certify that the person named above qualifies for BAP Training Membership on the grounds of (a) being a full or part-time student with a limited income OR (b) other reason (please specify)
SIGNATURE OF SPONSOR: ………………………………………. NAME (print): ………………………………..
Please send completed Application Form to the BAP Office 36 Cambridge Place, Hills Road, Cambridge CB2 1NS Tel: 44 (0) 1223 358 395 Fax: 44 (0) 1223 321 268 Email: [email protected] (Lynne Harmer, Assistant to the Executive Officer)
DO NOT SEND PAYMENT WITH THIS FORM
40 40 arrogate H 2013
2014 Pre-Clinical Certificate Residential Course
Royal Cambridge Hotel Trumpington Street Cambridge CB2 1PY
Sunday 23 to Wednesday 26 February 2014
In 2001 the BAP launched the Certificate in Pre-Clinical Psychopharmacology with the support of the BBSRC. The existing modular Certificate programme has been highly successful. The Certificate will now move to a new format and will become a 4 day residential course.
The aim of this programme is to increase awareness of, and interest in, experimental psychopharmacology through the provision of a cluster of training modules which will cover key aspects of research on animals and humans (as well as professional development in this field). The modules will have particular relevance to Home Office Licence holders as they will provide essential continuing professional development for researchers in industrial and academic centres whose work involves experiments on animals.
This course will benefit novice and experienced psychopharmacologists, as well as those working in related fields, by encouraging appraisal and refinement of experimental design, in addition to providing training in essential skills.
The following topics will be covered • Principles of Psychiatry • Pharmacokinetics in Psychiatry • The Molecular Biology of the Mind • Statistics and Experimental Design • Scientific Validity in Preclinical Psychopharmacology • Preclinical Models and Behavioural Psychopharmacology • Combining Neurobiology and Behaviour • Neuroimaging in Psychopharmacology
In addition to taught sections, the residential course will include round-table debates, practical sessions and a team project, and a full social programme.
Highlights Guest lectures will be given by Professor Barbara Sahakian (Cambridge), Professor David Nutt (London) and Professor Trevor Robbins (Cambridge)
To complete a registration of interest form, please go to www.bap.org.uk/educationevent.php?trainingTypeID=1
Course Directors Dr Paula Moran and Professor Hugh Marston
41 41 BAP Summer Meeting 28-31 July 2013
42 42 arrogate H 2013
43 43